John J. Nicols Cashes Out 35714 Shares of Codexis, Stock in 2023.
March 22, 2023
Trending News ☀️
John J. Nicols, an investor and current shareholder of Codexis ($NASDAQ:CDXS), Inc., has recently cashed out 35714 shares of the company’s stock. This transaction was completed in 2023 and has significantly reduced Nicols’ stake in the firm. Codexis, Inc. is a biotechnology company that focuses on developing enzymes for use in industrial and pharmaceutical applications. Nicols has been invested in the company since its inception and has seen a steady increase in its share price over the years.
However, the recent sale of his stock indicates that he may be looking to diversify his investments. It is unclear what motivated John J. Nicols to cash out his Codexis, Inc. shares, but speculation has arisen that the decision was made to take advantage of the strong performance that the company has been showing over recent years. Whatever the reason behind his decision, the sale of his shares has been completed and Nicols has reduced his stake in the company.
Price History
The news sentiment at the time of writing was mostly positive, with Codexis, Inc. stock opening at $3.9 and closing at the same price, down by 0.8% from its previous closing price of 3.9. This move by Nicols reflects his confidence in the company and its future prospects. It’s likely that investors will keep an eye on Codexis, Inc. and other stocks in the sector to see if this trend continues as the year progresses. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Codexis. More…
| Total Revenues | Net Income | Net Margin |
| 138.59 | -33.59 | -22.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Codexis. More…
| Operations | Investing | Financing |
| 11.28 | -13.58 | -0.57 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Codexis. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 250.39 | 105.6 | 2.2 |
Key Ratios Snapshot
Some of the financial key ratios for Codexis are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 26.5% | – | -22.9% |
| FCF Margin | ROE | ROA |
| 2.1% | -13.3% | -7.9% |
Analysis
GoodWhale has conducted an analysis of CODEXIS‘s wellbeing and found that it is a medium risk investment based on our Risk Rating. We detected two potential risks in their income and balance sheets, and to view these in more detail users will need to register with us. Our analysis revealed that CODEXIS is a viable investment option, with risks that should be considered before putting any money into it. We recommend that users carefully review the financial and business information of CODEXIS, as well as any other investments they are considering, to fully understand all the risks involved. By registering with us, users will gain access to our detailed analysis of CODEXIS, as well as additional resources, to help them make the best decision for their investments. More…
Peers
The biocatalysis and enzyme development market is expected to grow from USD 791.4 Million in 2019 to USD 1,162.6 Million by 2024, at a Compound Annual Growth Rate (CAGR) of 7.8% during the forecast period. The major players in the market are Codexis Inc (US), Biotest AG (Germany), ArcticZymes Technologies ASA (Norway), Microbix Biosystems Inc (Canada), and Advanced Enzymatic Solutions Inc (US).
– Biotest AG ($LTS:0N70)
Biotest AG is a biotechnology company that develops and manufactures immunoglobulins, blood plasma products, and recombinant proteins. The company has a market capitalization of 1.52 billion as of 2022 and a return on equity of -7.99%. The company’s products are used in the treatment of autoimmune diseases, immunodeficiencies, and hemophilia.
– ArcticZymes Technologies ASA ($LTS:0DRV)
ArcticZymes Technologies ASA is a biotechnology company that develops and markets enzymes and other biocatalysts. The company has a market cap of 3.6 billion as of 2022 and a return on equity of 14.85%. ArcticZymes is headquartered in Oslo, Norway.
– Microbix Biosystems Inc ($TSX:MBX)
Microbix Biosystems Inc is a Canadian biotechnology company that develops, manufactures, and sells in vitro diagnostic products and technologies. The company’s products are used in the fields of blood testing, infectious disease testing, and food safety testing. Microbix’s products are sold to government, hospitals, and commercial laboratories in over 50 countries worldwide. The company has a market cap of 68.8M as of 2022 and a Return on Equity of 11.51%.
Summary
Codexis, Inc. has been a prime target for investors in recent years, as a publicly traded biotechnology company focused on the development of enzyme-based products for the pharmaceuticals and chemicals industries. In 2023, John J. Nicols cashed out 35714 shares of Codexis stock, a move that was largely seen as positive by investors. Analysts have generally held Codexis in high regard, citing their diverse product portfolio, experienced management team and strong financial performance as key reasons to invest in the company. With their robust pipeline of products and their strategic partnerships with major pharmaceutical companies, Codexis appears well-positioned to capitalize on the growing biotechnology sector and deliver long-term returns to investors.
